Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 2Hematologic Neoplasms 2Granuloma, Plasma Cell 2Rhabdomyosarcoma 1Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, B-Cell 1Glioblastoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Irinotecan 7Cyclophosphamide 7Vincristine 6Magnetic Resonance Spectroscopy 5Dactinomycin 5temsirolimus 4cixutumumab 4X-Rays 4Sirolimus 4Radiotherapy 4Phantoms, Imaging 4Etoposide 4Doxorubicin 4Specimen Handling 3Radiation 3Peripheral Blood Stem Cell Transplantation 3Nuclear Medicine Department, Hospital 3Melphalan 3Ifosfamide 3Gemcitabine 3Filgrastim 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma × ceritinib × Clear all
NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡